Literature DB >> 33374124

Clinical Significance of Non-Invasive Prenatal Screening for Trisomy 7: Cohort Study and Literature Review.

Xiaofan Zhu1,2, Doris Yuk Man Lam3, Matthew Hoi Kin Chau2, Shuwen Xue2, Peng Dai1, Ganye Zhao1, Ye Cao2, Sunny Wai Hung Cheung3, Yvonne Ka Yin Kwok2, Kwong Wai Choy2,4,5, Xiangdong Kong1, Tak Yeung Leung2,4,5.   

Abstract

Trisomy 7 is the most frequently observed type of rare autosomal trisomies in genome-wide non-invasive prenatal screening (NIPS). Currently, the clinical significance of trisomy 7 NIPS-positive results is still unknown. We reviewed two independent cohorts from two laboratories where similar NIPS metrics were applied. A total of 70,441 singleton cases who underwent genome-wide NIPS were analyzed, among which 39 pregnancies were positive for trisomy 7, yielding a screen-positive rate of 0.055% (39/70,441). There were 28 cases with invasive testing results available; the positive predictive value (PPV) was 3.6% (1/28). We then searched the published NIPS studies to generate a large cohort of 437,873 pregnancies and identified 247 cases (0.056%) that were screened positive for trisomy 7. The overall PPV was 3.4% (4/118) in the combined data. The presence of uniparental disomy 7 was not detected in the NIPS trisomy 7-positive pregnancies with normal fetal karyotype. Among the 85 cases with pregnancy outcome available in combined data, 88.2% were normal live births, 14.1% had intrauterine growth restriction, preterm birth or low birth weight, 3.5% presented with ultrasound abnormality, and no fetal loss was observed. Our data provide valuable information for counseling and management of trisomy 7-positive NIPS pregnancies.

Entities:  

Keywords:  cell-free DNA screening; cell-free fetal DNA; non-invasive prenatal screening; trisomy 7; uniparental disomy 7

Mesh:

Substances:

Year:  2020        PMID: 33374124      PMCID: PMC7824243          DOI: 10.3390/genes12010011

Source DB:  PubMed          Journal:  Genes (Basel)        ISSN: 2073-4425            Impact factor:   4.096


  33 in total

1.  Rare autosomal trisomies: Important and not so rare.

Authors:  Fergus Scott; Michael Bonifacio; Rhiannon Sandow; Katie Ellis; Maria-Elisabeth Smet; Andrew McLennan
Journal:  Prenat Diagn       Date:  2018-07-17       Impact factor: 3.050

2.  Trisomy 7 CVS mosaicism: pregnancy outcome, placental and DNA analysis in 14 cases.

Authors:  D K Kalousek; S Langlois; W P Robinson; A Telenius; L Bernard; I J Barrett; P N Howard-Peebles; R D Wilson
Journal:  Am J Med Genet       Date:  1996-11-11

Review 3.  Clinical implementation of NIPT - technical and biological challenges.

Authors:  P Brady; N Brison; K Van Den Bogaert; T de Ravel; H Peeters; H Van Esch; K Devriendt; E Legius; J R Vermeesch
Journal:  Clin Genet       Date:  2015-05-04       Impact factor: 4.438

4.  Should we 'open the kimono' to release the results of rare autosomal aneuploidies following noninvasive prenatal whole genome sequencing?

Authors:  Diana W Bianchi
Journal:  Prenat Diagn       Date:  2017-01-24       Impact factor: 3.050

5.  Clinical utility of noninvasive prenatal screening for expanded chromosome disease syndromes.

Authors:  Desheng Liang; David S Cram; Hu Tan; Siyuan Linpeng; Yingdi Liu; Huaiyu Sun; Yu Zhang; Feng Tian; Hongmin Zhu; Mengnan Xu; Hua Wang; Fuli Yu; Lingqian Wu
Journal:  Genet Med       Date:  2019-03-04       Impact factor: 8.822

6.  Cell-free DNA analysis in maternal blood: comparing genome-wide versus targeted approach as a first-line screening test.

Authors:  Sidonie de Wergifosse; Elisa Bevilacqua; Iris Mezela; Sarah El Haddad; Caroline Gounongbe; Jérôme de Marchin; Valeria Maggi; Stéphanie Conotte; Dominique A Badr; Jean-François Fils; Meriem Guizani; Jacques C Jani
Journal:  J Matern Fetal Neonatal Med       Date:  2019-11-13

7.  Clinical utility of expanded non-invasive prenatal screening and chromosomal microarray analysis in high-risk pregnancy.

Authors:  X Zhu; M Chen; H Wang; Y Guo; M H K Chau; H Yan; Y Cao; Y K Y Kwok; J Chen; A S Y Hui; R Zhang; Z Meng; Y Zhu; T Y Leung; L Xiong; X Kong; K W Choy
Journal:  Ultrasound Obstet Gynecol       Date:  2021-03       Impact factor: 7.299

8.  Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics.

Authors:  Anthony R Gregg; Brian G Skotko; Judith L Benkendorf; Kristin G Monaghan; Komal Bajaj; Robert G Best; Susan Klugman; Michael S Watson
Journal:  Genet Med       Date:  2016-07-28       Impact factor: 8.822

9.  Trial by Dutch laboratories for evaluation of non-invasive prenatal testing. Part I-clinical impact.

Authors:  Dick Oepkes; G C Lieve Page-Christiaens; Caroline J Bax; Mireille N Bekker; Catia M Bilardo; Elles M J Boon; G Heleen Schuring-Blom; Audrey B C Coumans; Brigitte H Faas; Robert-Jan H Galjaard; Attie T Go; Lidewij Henneman; Merryn V E Macville; Eva Pajkrt; Ron F Suijkerbuijk; Karin Huijsdens-van Amsterdam; Diane Van Opstal; E J Joanne Verweij; Marjan M Weiss; Erik A Sistermans
Journal:  Prenat Diagn       Date:  2016-11-15       Impact factor: 3.050

10.  Validation Studies for Single Circulating Trophoblast Genetic Testing as a Form of Noninvasive Prenatal Diagnosis.

Authors:  Liesbeth Vossaert; Qun Wang; Roseen Salman; Anne K McCombs; Vipulkumar Patel; Chunjing Qu; Michael A Mancini; Dean P Edwards; Anna Malovannaya; Pengfei Liu; Chad A Shaw; Brynn Levy; Ronald J Wapner; Weimin Bi; Amy M Breman; Ignatia B Van den Veyver; Arthur L Beaudet
Journal:  Am J Hum Genet       Date:  2019-11-27       Impact factor: 11.025

View more
  2 in total

1.  Pregnancy outcomes of rare autosomal trisomies results in non-invasive prenatal screening: clinical follow-up data from a single tertiary centre.

Authors:  Ying Lin; Ping Hu; Hang Li; Chunyu Luo; Dong Liang; Zhengfeng Xu
Journal:  J Cell Mol Med       Date:  2022-02-16       Impact factor: 5.310

2.  Prenatal diagnosis of trisomy 8 mosaicism, initially identified by cffDNA screening.

Authors:  Junjie Hu; Kai Yan; Pengzhen Jin; Yanmei Yang; Yixi Sun; Minyue Dong
Journal:  Mol Cytogenet       Date:  2022-09-01       Impact factor: 1.904

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.